Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) has a cash flow conversion efficiency ratio of 0.144x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($118.45 Million) by net assets ($819.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AMRX equity to assets ratio to measure how much of total assets are equity-financed.
Amneal Pharmaceuticals, Inc. Class A Common Stock - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Amneal Pharmaceuticals, Inc. Class A Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check AMRX operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Amneal Pharmaceuticals, Inc. Class A Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amneal Pharmaceuticals, Inc. Class A Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hebei Changshan Biochem Pharma
SHE:300255
|
-0.021x |
|
China Coal Xinji Energy Co Ltd
SHG:601918
|
0.053x |
|
Olav Thon Eien
OL:OLT
|
0.000x |
|
Hinge Health, Inc.
NYSE:HNGE
|
0.169x |
|
RUBIS
F:BYN
|
N/A |
|
Quálitas Controladora S.A.B. de C.V.
MX:Q
|
0.103x |
|
Sinomach Heavy Equipment Group Co Ltd
SHG:601399
|
-0.020x |
|
Premium Brands Holdings Corporation
TO:PBH
|
-0.003x |
Annual Cash Flow Conversion Efficiency for Amneal Pharmaceuticals, Inc. Class A Common Stock (2015–2024)
The table below shows the annual cash flow conversion efficiency of Amneal Pharmaceuticals, Inc. Class A Common Stock from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Amneal Pharmaceuticals, Inc. Class A Com.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-44.54 Million | $295.10 Million | -6.626x | -138.37% |
| 2023-12-31 | $20.01 Million | $345.58 Million | 17.269x | +5442.32% |
| 2022-12-31 | $208.93 Million | $65.10 Million | 0.312x | -52.71% |
| 2021-12-31 | $366.97 Million | $241.82 Million | 0.659x | -40.03% |
| 2020-12-31 | $344.93 Million | $379.00 Million | 1.099x | +22248.41% |
| 2019-12-31 | $346.79 Million | $1.71 Million | 0.005x | -98.24% |
| 2018-12-31 | $896.36 Million | $250.23 Million | 0.279x | +144.77% |
| 2017-12-31 | $-375.58 Million | $234.19 Million | -0.624x | +4.65% |
| 2016-12-31 | $-175.94 Million | $115.06 Million | -0.654x | -16.52% |
| 2015-12-31 | $-186.87 Million | $104.88 Million | -0.561x | -- |
About Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate an… Read more